Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt
Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for "restricted emergency use" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection
- Jul 13, 2020,
- Updated Jul 13, 2020 7:42 PM IST
In wake of rising demand for antiviral drug Remdesivir used for coronavirus treatment, homegrown drug major Cipla has ramped up its capacity and that of its partner network to fill the demand-supply gap. Last month, the company launched the generic version of Gilead Sciences' antiviral drug Remdesivir under its brand name 'CIPREMI'.
"Our first batch of Remdesivir vials was supplied to hospitals and distributors across India, especially in the regions with high burden of COVID-19 cases. However given the spike in cases, the demand has increased manifold," Cipla said in a statement. "We expect this demand-supply gap to normalised in the next few weeks."
In June, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from Drugs Controller General of India (DCGI) for "restricted emergency use" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection. The company has priced the antiviral drug Remdesivir at Rs 4,000 per vial. A patient would need five vials of the drug.
In wake of rising demand for antiviral drug Remdesivir used for coronavirus treatment, homegrown drug major Cipla has ramped up its capacity and that of its partner network to fill the demand-supply gap. Last month, the company launched the generic version of Gilead Sciences' antiviral drug Remdesivir under its brand name 'CIPREMI'.
"Our first batch of Remdesivir vials was supplied to hospitals and distributors across India, especially in the regions with high burden of COVID-19 cases. However given the spike in cases, the demand has increased manifold," Cipla said in a statement. "We expect this demand-supply gap to normalised in the next few weeks."
In June, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from Drugs Controller General of India (DCGI) for "restricted emergency use" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection. The company has priced the antiviral drug Remdesivir at Rs 4,000 per vial. A patient would need five vials of the drug.